495 related articles for article (PubMed ID: 33722275)
1. Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
Al Zahrani A; Alfakeeh A
J Med Case Rep; 2021 Mar; 15(1):132. PubMed ID: 33722275
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
[TBL] [Abstract][Full Text] [Related]
5. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
[TBL] [Abstract][Full Text] [Related]
8. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Hou Y; Wu B
Cancer Commun (Lond); 2020 Dec; 40(12):743-745. PubMed ID: 33159490
[No Abstract] [Full Text] [Related]
10. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
Komatsu S; Fujishima Y; Kido M; Kuramitsu K; Goto T; Yanagimoto H; Toyama H; Fukumoto T
BMC Gastroenterol; 2021 Dec; 21(1):470. PubMed ID: 34911458
[TBL] [Abstract][Full Text] [Related]
11. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma.
D'Alessio A; Cammarota A; Zanuso V; Pressiani T; Personeni N; Rimassa L
Expert Rev Anticancer Ther; 2021 Sep; 21(9):927-939. PubMed ID: 34167423
[No Abstract] [Full Text] [Related]
13. An update on atezolizumab for hepatocellular carcinoma.
Ielasi L; Sansone V; Forgione A; Granito A; Benevento F; Tovoli F
Drugs Today (Barc); 2021 Jun; 57(6):365-375. PubMed ID: 34151903
[TBL] [Abstract][Full Text] [Related]
14. Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.
Han JW; Jang JW
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511558
[TBL] [Abstract][Full Text] [Related]
15. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Niizeki T; Montes M; Vivaldi C; Soldà C; Stefanini B; Hiraoka A; Sho T; Nishida N; Steup C; Iavarone M; Di Costanzo G; Marra F; Tamburini E; Cabibbo G; Foschi FG; Silletta M; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Campani C; Amadeo E; Rossari F; Burgio V; Cascinu S; Scartozzi M; Casadei-Gardini A
Eur J Cancer; 2023 Aug; 189():112933. PubMed ID: 37385069
[TBL] [Abstract][Full Text] [Related]
16. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
Minot-This MS; Edeline J
Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
[No Abstract] [Full Text] [Related]
17. Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report.
Kumar P; Krishna P; Nidoni R; Adarsh CK; Arun MG; Shetty A; Mathangi J; Sandhya ; Gopasetty M; Venugopal B
Am J Transplant; 2024 Jun; 24(6):1087-1090. PubMed ID: 38219868
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.
Gao X; Zhao R; Ma H; Zuo S
BMC Cancer; 2023 Jul; 23(1):635. PubMed ID: 37415136
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
Özdirik B; Jost-Brinkmann F; Savic LJ; Mohr R; Tacke F; Ploner CJ; Roderburg C; Müller T
Medicine (Baltimore); 2021 Jun; 100(24):e26377. PubMed ID: 34128898
[TBL] [Abstract][Full Text] [Related]
20. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
